Matarki Bioscience has been spun out under a drug discovery model to carry Warsaw pharmaceutical research through pre-clinical and early clinical trials.

University of Warsaw has launched Poland-based drug discovery spinout Matariki Bioscience to develop compounds with therapeutic potential discovered at the peptides laboratory in the Faculty of Chemistry.

Matariki Bioscience will take forward Warsaw candidates targeting conditions such as chronic pain or cancer.

The company will focus on drug discovery, playing a hand in selecting assets for pre-clinical and early clinical trials in the hope they impress major pharmaceutical firms enough to fund later and more costly clinical experiments.

University of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?